Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)

被引:0
|
作者
Vis, AN
Hoedemaeker, RF
Roobol, M
van der Kwast, TH
Schröder, FH
机构
[1] Erasmus Univ, Josephine Nefkens Inst, Dept Pathol, NL-3000 DR Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Dept Urol, Rotterdam, Netherlands
来源
PROSTATE | 2001年 / 47卷 / 04期
关键词
screening; prostate cancer; tumor characteristics; rectal examination;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The value of rectal examination as initial screening test for prostate cancer at low PSA values (0.0-3.9 ng/ml) was determined by evaluating the number and tumor characteristics of the cancers detected. METHODS. Two study populations were subjected to screening with (n=10,226) and without (n=10,753) rectal examination as initial screening test. The number of cancers detected at low PSA values for both screening regimens, the corresponding biopsy and radical prostatectomy tumor characteristics were assessed. Possibly harmless cancers were defined as small (< 0.5 ml) organ-confined humors without Gleason growth-patterns 4/5. RESULTS. At low PSA, 26.6% (117/440) of screen-detected cancers were detected after the evaluation of a suspicious rectal examination. The number of cancers and tumor aggressiveness features were highly associated with serum-PSA level. The proportion of possibly harmless disease steadily declined from 100% (PSA 0.0-0.9 ng/ml) to 15.4% (PSA 3.0-3.9 ng/ml). Rectal examinations were performed unnecessarily in 94.7-100% of cases, when detection of clinically significant disease was aimed at. Using PSA (and a cut-off of 3.0 ng/ml) as the only screening tool, 24.3% (121/498) of screen-detected cancers were in the PSA range 3.0-3.9 ng/ml, and 60.0% were assessed as clinically significant. CONCLUSIONS. Rectal examination as initial screening test for prostate cancer at low PSA values may be replaced by screening using serum-PSA only. At PSA levels below 3.0 ng/ml, 289 rectal examinations are required to find one case of clinically significant disease, and 96 rectal examinations are needed to diagnose prostate cancer of any size, grade, or stage. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:252 / 261
页数:10
相关论文
共 50 条
  • [1] Screening for prostate cancer at low PSA range:: The impact of digital rectal examination on tumor incidence and tumor characteristics
    Gosselaar, Claartje
    Roobol, Monique J.
    Roemeling, Stijn
    van der Kwast, Theo H.
    Schroder, Fritz H.
    [J]. PROSTATE, 2007, 67 (02): : 154 - 161
  • [2] Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial
    Soronen, Veera
    Talala, Kirsi
    Raitanen, Jani
    Taari, Kimmo
    Tammela, Teuvo
    Auvinen, Anssi
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2021, 55 (05) : 348 - 353
  • [3] Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.:: A comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests
    Mäkinen, T
    Tammela, TLJ
    Hakama, M
    Stenman, UH
    Rannikko, S
    Aro, J
    Juusela, H
    Määttänen, L
    Auvinen, A
    [J]. JOURNAL OF UROLOGY, 2001, 166 (04): : 1339 - 1342
  • [4] A "PSA Pyramid'' for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening
    Randazzo, Marco
    Beatrice, Josef
    Huber, Andreas
    Grobholz, Rainer
    Manka, Lukas
    Chun, Felix K.
    Recker, Franz
    Kwiatkowski, Maciej
    [J]. EUROPEAN UROLOGY, 2015, 68 (04) : 591 - 597
  • [5] Delays in cancer detection using 2 and 4 year screening intervals for prostate cancer screening in men with initial PSA &lt; 2 ng/ml
    Grubb, RL
    Roehl, KA
    Antenor, JAV
    Catalona, WJ
    [J]. JOURNAL OF UROLOGY, 2002, 167 (04): : 100 - 100
  • [6] ProPSA improves prostate cancer detection and tumor aggressiveness in PSA range 2.0-3.9 ng/ml
    Raaijmakers, R
    De Vries, SH
    Blijenberg, BG
    Mikolajczyk, SD
    Rittenhouse, HG
    Schröder, FH
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 439 - 439
  • [7] Evaluation of the digital rectal examination as a screening test for prostate cancer
    Schroder, FH
    van der Maas, P
    Beemsterboer, P
    Kruger, AB
    Hoedemaeker, R
    Rietbergen, J
    Kranse, R
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (23) : 1817 - 1823
  • [8] Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer
    Krilaviciute, Agne
    Becker, Nikolaus
    Lakes, Jale
    Radtke, Jan Philipp
    Kuczyk, Markus
    Peters, Inga
    Harke, Nina N.
    Koerber, Stefan A.
    Herkommer, Kathleen
    Gschwend, Jurgen E.
    Meissner, Valentin H.
    Benner, Axel
    Seibold, Petra
    Kristiansen, Glen
    Hadaschik, Boris
    Arsov, Christian
    Schimmoeller, Lars
    Giesel, Frederik Lars
    Antoch, Gerald
    Makowski, Marcus
    Wacker, Frank
    Schlemmer, Heinz-Peter
    Kaaks, Rudolf
    Albers, Peter
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (06): : 566 - 573
  • [9] Prostate cancer detection in prostate specific antigen (PSA) range 2.0-3.9 ng/ml -: A study without verification bias
    Raaijmakers, R
    De Vries, SH
    Schröder, FH
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 475 - 475
  • [10] The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml
    Pashtan, Itai
    Chen, Ming-Hui
    D'Amico, Anthony V.
    [J]. CANCER EPIDEMIOLOGY, 2014, 38 (05) : 613 - 618